Oncology Corporate Profile
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. The Company has clinical programs in small RNA therapeutics and obesity. Arrowhead's programs are based on its proprietary drug development and delivery platforms, each capable of creating multiple therapeutic products. This strategy seeks to enhance the return potential for investors and reduce risk compared to traditional biotech companies. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to optimize therapeutic agents for a wide range of diseases.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|cyclosert / CRLX-101||topoisomerase I inhibitor||Non Small Cell Lung Cancer (NSCLC)||II||Cerulean Pharma, Inc.|
|CALAA-01||RNAi therapeutic||Various cancer types||I||Calando Pharmaceuticals|
|cyclosert / CRLX-101||topoisomerase I inhibitor||Various cancer types||Preclinical||Tube Pharma|
|Unnamed||RNA antagonist (HIF-1 alpha antagonist)||Various cancer types||Research|
View additional information on product candidates here »